RxDoctor Payments Data

Kacey Blaylock

Optometrist · Boise, IDNPI 1164871489

Payments from drug & device makers

$1,556in general payments, 2019–2025

Across 52 payments — averaging $29.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$317
  • Biotissue Holdings Inc.$165
  • Rxsight Inc$157
  • Harrow Eye, LLC$128
  • Shire North American Group Inc$120
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$119
  • plus $550 from 11 others

What the payments were for

  • Consulting fees$1208%
  • Speaking & faculty fees$262%
  • Food & beverage$1,41091%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,556 in reported general payments places this provider in the 75th percentile of 304 optometrist providers in Idaho.

See all optometrist providers in Idaho

Medicare billing

Part B allowed, 2024
$154,746
Medicare patients
888
Services billed
1,699

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine29$28,851
Cyclosporine36$8,671
LumiganBimatoprost14$7,858
Prednisolone Acetate113$3,857
ErythromycinErythromycin Base219$3,006
Brimonidine Tartrate22$1,396
Latanoprost281$1,385
ValacyclovirValacyclovir Hcl21$1,243
Fluorometholone14$1,022
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha68$783
Doxycycline Hyclate18$740
Timolol Maleate70$289
Ofloxacin12$130
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat11$123

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$110$36,70943 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 304 optometrist providers in Idaho.

Other optometrist in Boise

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →